Clinical Significance of ERCC1 and RRM1 in Non Small Cell Lung Cancer: Comparison between Adenocarcinoma and Squamous Cell Carcinoma
의약학 > 내과학
( Yong Chul Lee ) , ( So Ri Kim ) , ( Seon Min Kim ) , ( Yang Keun Rhee ) , ( Heung Bum Lee ) , ( Seoung Ju Park ) , ( Chi Ryang Chung ) , ( Seung Yong Park )
대한결핵 및 호흡기학회
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 289(총1페이지)
0y910076.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    The expression of excision repair cross-complementing group 1 (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) has been reported to relate with the survival and response of chemotherapy for lung cancer, especially non-small cell lung cancer (NSCLC). However, there is little information on the differences in their expressions and clinical significances between squamous cell carcinoma (SqCC) and adenocarcinoma (ADC). This retrospective analysis was performed on 100 patients diag-nosed as NSCLC pathologically from March 2011 in a teaching hospital. The quantified results of expression of ERCC and RRM1 showed that the mean IRS of ERCC1 and RRM1 were 4.77 and 3.54. Interestingly, the values of ERCC1 in male patients was higher than those of woman (4.94 vs. 4.59 [p=0.004]). As for the histologic stratification, the mean ERCC1 IRS for ADC and SqCC showed no significant difference, whereas the mean RRM1 IRS for ADC and SqCC were 3.33 and 3.94, respectively (p=0.005). In analyses according to stage at the diagnosis and response to the treatment, the mean IRS of ERCC1 and RRM1 did not show the significant difference statistically. These findings suggest that RRM1 may be more expressed in SqCC than in ADC and that despite the several previous reports, the clinical significance of ERCC and RRM1 as biomarkers in NSCLC is still controversial.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일
    copyright (c) 2009 happynlife. steel All reserved.